Opinion|Videos|September 6, 2024
Future Directions for Type 2 Inflammation Management
Author(s)Reynold A. Panettieri Jr, MD
Reynold A. Panettieri Jr., MD, examines the application of biologic therapies in the treatment of respiratory conditions.
Advertisement
Episodes in this series
- Biologics are currently available for asthma management and being studied in COPD patients. Where do you envision the potential place of biologic therapies in the treatment algorithm for patients with type 2 inflammation-driven COPD?
- How does the route of administration impact the treatment selection?
- What emerging therapies for type 2 inflammation related to respiratory diseases are you most excited about? What are clinical trial data showing in terms of exacerbation and hospitalization rates, patient quality of life, and general disease management?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Emerging Data Suggest Survodutide Targets Liver Fat More Rapidly Than Weight Loss: Lee Kaplan, MD, PhD
2
Cicada COVID-19 Variant FAQs: Symptoms, Risk, and Prevention
3
Survodutide Normalizes Liver Fat in 61% of Patients With MASLD in Phase 3 Trial: Lee Kaplan, MD, PhD
4
Social Factors Shape Diabetes, Dementia Risk Across Populations
5